Compare Charles River Laboratories Intl. Inc (CRL) vs MicroSectors FANG and Innovation 3X Leveraged ETN (FNGU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs MicroSectors FANG and Innovation 3X Leveraged ETN — how do they compare? Charles River Laboratories Intl. Inc trades at $227.69 (market cap $11.14B), while MicroSectors FANG and Innovation 3X Leveraged ETN trades at $29.8. The key difference: Charles River Laboratories Intl. Inc is trading nearer its 52-week high, MicroSectors FANG and Innovation 3X Leveraged ETN nearer its low. Which is the better fit depends on your goals.
| CRL | FNGU | |
|---|---|---|
Market Cap | $11.14B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $233.60 | $36.15 |
52-Week Low | $145.57 | $13.73 |
Enterprise Value | $14.00B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
FNGU, a leveraged ETN tracking the FANG+ Index, trades at $27.9, down 2.58% on the day. Technical indicators show a bullish moving average signal but caution from oscillators, with the 12-day RSI at 70.17 indicating potential overbought conditions. Recent news highlights extreme volatility, with a 16% single-session loss reported on June 5, 2026, underscoring the inherent risks of leveraged products.
The outlook for FNGU is highly speculative, driven by daily rebalancing and leverage amplifying both gains and losses. Investment opportunity exists for aggressive traders betting on short-term tech sector strength, but risks include rapid capital erosion during market downturns and structural costs from the 0.95% fee and leverage decay, as noted in recent financial media.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About MicroSectors FANG and Innovation 3X Leveraged ETN
FNGU is a leveraged ETN that seeks to provide three times (3x) the daily performance of top tech and innovation stocks. It is intended for traders seeking magnified short-term returns.
Read more on FNGU →
